Alten

Quick links to important sections

Alten

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alten

What is Alten? Defining Its Medical Identity

Property Description
Active Ingredient Atorvastatin (INN)
Form Film-coated Oral Tablet
Pharmacological Class HMG-CoA Reductase Inhibitor (Statin)
Typical Use Managing high cholesterol/lipid levels
Origin Synthetic Compound

Alten is the established brand name for a prescription drug containing the active ingredient Atorvastatin, which belongs to the pharmacological class known as HMG-CoA Reductase Inhibitors (Statins). This class of medicine is clinically recognized for its ability to significantly reduce low-density lipoprotein (LDL) cholesterol—often termed "bad" cholesterol—in the blood. Drugs in this category are used to reduce the risk of cardiovascular events in at-risk patients, making the medicine a primary tool used to prevent serious complications like heart attack and stroke.


Composition and Origin: Unique Features of Alten

Alten is fundamentally a synthetic compound manufactured through a precise chemical process. As a brand, Alten provides the generic Atorvastatin in a film-coated oral tablet form designed for reliable, systemic absorption. Alten is typically positioned for patients who require long-term, stable lipid control as part of a comprehensive management plan. The formulation focuses on ensuring high consistency across various dosage strengths, as the long-term effectiveness of statin therapy relies on uninterrupted, stable administration.


Primary Therapeutic Use: Why is Alten Prescribed?

The core therapeutic purpose of Alten is the management of chronic dyslipidemia, a condition involving unhealthy levels of fats (lipids) in the bloodstream. It is broadly prescribed to lower cholesterol and triglyceride levels as a primary risk-reduction strategy for cardiovascular disease. By controlling these key risk factors, Alten helps to stabilize the health of the blood vessels, making it a cornerstone of preventive cardiac care.

What side effects are possible with Alten?

Possible Side Effects and Safety Information

The safety profile of Alten (Atorvastatin) is officially documented and categorized by regulatory authorities, focusing on specific adverse reactions and usage restrictions. The documented effects are organized by frequency and the body system affected, reflecting observations from clinical trials and post-marketing experience.

Frequency-Classified Adverse Reactions

The following is a high-level summary of adverse reactions classified by frequency in regulatory documents:

Classification Examples of Reactions Affected Systems (SOC)
Common Nasopharyngitis, Headache, Myalgia, Diarrhea, Constipation, Increased blood glucose levels, Abnormal liver function tests. Infections, Nervous, Musculoskeletal, Gastrointestinal
Uncommon Insomnia, Dizziness, Pancreatitis, Peripheral neuropathy, Weight gain. Psychiatric, Nervous, Gastrointestinal
Rare Myopathy, Rhabdomyolysis, Hepatitis, Cholestasis, Angioedema. Musculoskeletal, Hepatobiliary, Immune
Very Rare Hepatic failure, DRESS. Hepatobiliary, Skin

Serious Safety Considerations

The drug label highlights serious adverse reactions that are rare but clinically significant. These include Rhabdomyolysis, a severe muscle condition that can potentially lead to acute renal failure, and serious liver effects such as Hepatitis and Hepatic failure. Other serious reactions explicitly documented include Immunologically-Mediated Necrotizing Myopathy and severe hypersensitivity reactions like Angioedema.

Population and Constraint Safety Notes

Official prescribing information defines specific safety constraints. Alten is contraindicated in individuals with active liver disease or unexplained persistent elevations of serum transaminases, and also during pregnancy and breastfeeding. Furthermore, advanced age (65 years and older) is recognized as a factor associated with an increased risk of musculoskeletal disorders like myopathy.

Overdose and Emergency Response

The regulatory documents for Alten (Atorvastatin) define the management of overdosage by focusing on supportive care and the potential for severe systemic injury.

Documented Overdose Profile and Emergency Action

The official prescribing information confirms that no specific treatment or antidote is known for Atorvastatin overdosage. Management must be restricted to treating the patient symptomatically and instituting supportive measures as clinically required.

Documented Severe Outcomes: Overexposure to Alten is associated with the risk of severe systemic toxicity. The primary documented risks requiring urgent attention include:

  • Rhabdomyolysis: Breakdown of muscle tissue, often indicated by markedly elevated Creatine Kinase (CK) levels.
  • Acute Renal Failure: Potential complication secondary to Rhabdomyolysis.
  • Fatal Hepatic Failure: Rare, serious liver injury.

Required Emergency Action: Immediate action is mandatory if an overdose is suspected. Government guidance instructs the individual to call a Poison Control Center or seek immediate medical attention at the nearest emergency facility. Emergency services must be contacted immediately if the patient displays life-threatening signs, such as collapse, a seizure, trouble breathing, or the inability to be awakened. The regulatory labeling notes that due to the drug's high plasma protein binding, hemodialysis is unlikely to significantly enhance clearance.

Therapeutic Uses of Alten

Quick Facts: Alten’s Therapeutic Domains

  • Addresses: High cholesterol (hypercholesterolemia)
  • Goal: Aids in the reduction of certain blood lipid levels
  • Benefit: Helps manage the risk of cardiovascular events, including heart attack and stroke
  • Application: Used when dietary measures and lifestyle changes alone have not provided adequate cholesterol reduction

Alten is a medication prescribed to manage high levels of cholesterol and triglycerides in the blood. The primary purpose of this treatment is to help patients reduce elevated lipid levels that may contribute to cardiovascular concerns. It is typically considered when modifications to diet and exercise have not been sufficient in reaching cholesterol goals.

By helping to lower the amount of low-density lipoprotein (LDL), often called “bad” cholesterol, Alten is an option that may decrease the overall risk of heart conditions, including heart attack and stroke. This therapeutic approach is a component of a comprehensive plan for lipid management, often prescribed to individuals with established cardiac risk factors or specific types of familial lipid disorders. The use of this drug is intended to support the reduction of cardiovascular events by maintaining balanced lipid levels. This class of medication is intended for use under medical supervision as part of a structured cardiovascular health strategy.

Eligibility and Restrictions for Use

Alten (atorvastatin) is not suitable for all patient populations. Eligibility for the drug is strictly defined by regulatory authorities based on certain medical conditions and demographic factors.

Populations for whom use is allowed (as stated in label):

  • Adult patients requiring treatment for high cholesterol or cardiovascular risk reduction.
  • Pediatric patients aged 10 years and older for specific genetic lipid disorders (Heterozygous and Homozygous Familial Hypercholesterolemia).

Populations for whom use is contraindicated:

Classification Exclusion Criteria (Must Not Use)
Organ Status Active liver disease, including unexplained persistent elevated liver enzyme levels.
Reproductive Status Women who are pregnant, breastfeeding, or of child-bearing potential not using effective contraception.
Allergy Known hypersensitivity or allergy to atorvastatin or any component of the medication.

Eligibility-Related Restrictions

Use of Alten requires caution or is limited in patients with certain risk factors for muscle damage (myopathy) as documented in official labeling. These populations include individuals with advanced age (65 years and older), renal impairment, and uncontrolled hypothyroidism. Safety and effectiveness have not been established in children younger than 10 years of age for any condition.

What should I know about interactions with other medicines?

Alten’s (Atorvastatin) official interaction profile is structured around two key categories: those that significantly alter drug exposure and those that pose an additive risk.

The product's interactions are documented with strong and moderate CYP3A4 inhibitors, HCV protease inhibitors, OATP/BCRP uptake transporter inhibitors, fibrates, Niacin (1 gram or greater per day), oral contraceptives, antacids, and Digoxin. These interacting substances lead to constraints defined by regulatory authorities.

Official interaction statements categorize combinations that significantly raise Alten’s systemic levels (pharmacokinetic interactions) or increase the risk of skeletal muscle effects (pharmacodynamic interactions). Strong CYP3A4 inhibitors and OATP transporter inhibitors, such as Cyclosporine, cause clinically significant increases in exposure. Certain HCV protease inhibitors (e.g., Glecaprevir/Pibrentasvir) are formally contraindicated in co-administration due to the extreme increase in Alten’s plasma concentration.

Interactions requiring specific administration rules include Rifampin, where co-administration must be simultaneous to prevent an approximately 80% loss in Alten’s plasma concentrations. Pharmacodynamic interactions with fibrates and high-dose Niacin carry an additive risk of myopathy and rhabdomyolysis. Consumption of excessive grapefruit juice (greater than 1.2 liters daily) is documented to increase Alten’s plasma concentration. Additionally, Alten co-administration increases the plasma concentrations of certain oral contraceptives and Digoxin. The documented risk is also relevant for patients with hepatic impairment, as their condition can lead to increased Alten exposure.

Mechanism of Action

Inhibition of Hepatic Cholesterol Synthesis

Alten (Atorvastatin) functions by engaging the key enzyme HMG-CoA Reductase in the liver and acting as a competitive inhibitor to block its activity. This molecular action restricts the rate-limiting step of the Mevalonate pathway, resulting in reduced internal (endogenous) production of cholesterol within the liver cells.


Regulation Through Enhanced LDL Receptor Clearance

The resulting reduction of internal cholesterol triggers a homeostatic feedback mechanism, causing liver cells to increase the expression of LDL Receptors displayed on their surface. This physiological change accelerates the clearance and systemic removal of circulating LDL-cholesterol and other atherogenic lipoprotein remnants from the bloodstream.


Vascular and Endothelial Modulation

Beyond its core lipid-lowering cascade, the mechanism of Alten includes independent pleiotropic effects that occur within the arterial walls. This involves increasing the bioavailability of Nitric Oxide (NO), which influences endothelial function, and modulating local inflammatory activity within the vessel lining.

Dosage and Administration Information

How Alten is Used: Administration Guidelines

Alten is formulated as an oral, film-coated tablet and is administered as part of a long-term, continuous management plan. The instructions for its use are standardized to ensure consistent administration.

Dosage and Frequency

The dosage range for adults is 10 mg to 80 mg once daily. The initial starting dose is typically 10 mg or 20 mg once per day. For instances requiring a large reduction in blood lipid levels (a reduction in LDL-C of over 45%), a starting dose of 40 mg once daily may be used. The maximum daily dose is 80 mg.

Administration Timing and Adjustments

Alten can be taken as a single dose at any time of the day, with the tablet swallowed whole. It is used with or without food. Dosage adjustments, if required after treatment initiation, should be made at intervals of four weeks or more, based on clinical evaluation.

Rules for Specific Scenarios

  • Missed Dose: If a dose is missed, the patient should skip the missed dose and resume the regular schedule with the next scheduled dose; doubling the dose to compensate is not permitted.
  • Renal Impairment: No dosage adjustment is necessary for patients with impaired kidney function.
  • Pediatric Use: For pediatric patients 10 years and older with Heterozygous Familial Hypercholesterolemia (HeFH), the recommended starting dose is 10 mg once daily, with the maximum dose limited to 20 mg per day.

Recent Clinical Evidence

Research evidence / Overview of studies for Alten (Atorvastatin)


Research Evidence in Established Cardiovascular Disease

The research base for the active ingredient in Alten, Atorvastatin, in individuals with established Atherosclerotic Cardiovascular Disease (ASCVD) includes large-scale, long-term Randomized Controlled Trials (RCTs) and meta-analyses. These studies monitored the incidence of outcomes related to fatal coronary heart disease, non-fatal heart attack, stroke, and the need for corrective vascular procedures over several years. Findings describe patterns observed where the occurrence of serious cardiovascular events was assessed between groups that received Atorvastatin and those that received a placebo or active comparator. Research highlights changes measured in LDL cholesterol and other lipid markers between groups. Long-term follow-up data has been gathered, though the evidence quality varies for extended periods where the controlled, blinded nature of the initial trials is lost.


Research Evidence in High-Risk Primary Prevention

Research also explored the study of Atorvastatin in high-risk adults who had not yet experienced a major cardiovascular event. These RCTs measured the incidence of a first serious event, such as a heart attack or stroke. Studies describe patterns related to the first occurrence of cardiovascular events and consistently reported measurements of LDL cholesterol levels across the observed time intervals. However, the certainty remains low for some specific demographic groups. Data for adults aged 76 and older who do not have established ASCVD remain insufficient, and research in this area is ongoing.


Studies on Lipid Biomarker Modification

Atorvastatin was evaluated in research exploring systemic or functional imbalance related to blood lipid levels. The evidence base here largely relies on short- to intermediate-term RCTs that focus on measurable biomarker shifts, including LDL cholesterol, Total Cholesterol, and Triglycerides. Findings describe patterns consistently reporting that differences measured in lipid biomarkers were observed based on the dosage used in the research scenario. The link between these short-term biomarker shifts and the long-term clinical outcomes is often characterized using data from the larger, multi-year prevention trials.


Evidence in Specific Patient Populations

Research was conducted in pediatric patients (boys and postmenarchal girls, 10 to 17 years) with heterozygous familial hypercholesterolemia (HeFH) to monitor changes in lipid biomarkers. The findings describe lipid biomarker patterns observed in this younger population, which was evaluated in research exploring similar outcomes to adult groups. However, the sample sizes were modest and follow-up durations were limited in the pediatric trials. For older adults without heart disease, data are still emerging, meaning there is limited information for long-term outcomes specifically defining the effect profile in this advanced age group.

Frequently Asked Questions (FAQ)

Common questions about Alten (FAQ)


Q: How quickly does Alten start to work?

Official information indicates that a measurable therapeutic response is typically observed in patients within two weeks of starting treatment. The maximum, full cholesterol-lowering effect is usually reached after approximately four weeks of continuous administration.


Q: What are the most common side effects people report with Alten?

According to official product information, the most commonly reported adverse reactions include cold-like symptoms such as nasopharyngitis (stuffy or runny nose and sore throat) and general discomfort like headache, muscle or joint pain, and digestive issues like diarrhea or upset stomach.


Q: Is it normal to feel tired when you first start taking Alten?

General tiredness is not specifically listed as a common, minor effect during the initial adjustment period. However, official safety documentation notes that feeling easily tired or having low energy levels can sometimes be a sign associated with rare but clinically serious muscle issues, which are conditions noted in safety documents as requiring professional monitoring.


Q: Is Alten safe for people who have kidney issues?

Studies and official prescribing information indicate that the drug's processing in the body is not significantly altered by impaired kidney function. Therefore, no dosage adjustment is necessary for patients with impaired kidney function.


Q: Does Alten interact with common stomach acid reducers?

Official documents describe an interaction with certain stomach acid reducers. Taking Alten at the same time as an oral suspension antacid that contains magnesium and aluminum hydroxides may reduce the amount of Alten in the bloodstream by approximately 35%.


Q: Can I take Alten with my daily vitamin supplements?

No major or clinically significant interactions have been specifically documented between Alten and common vitamin supplements. However, the official advisories include informing a healthcare provider of all prescription medicines, over-the-counter drugs, and supplements being taken.


Q: Why do some people experience trouble sleeping on Alten?

Official adverse reaction data lists trouble sleeping, or insomnia, as an uncommon side effect of this medicine. The specific clinical mechanism or cause for why this effect occurs in some patients is not detailed in the product label.


Q: Is Alten considered a high-risk medication?

Official documents describe the safety profile by defining specific contraindications (conditions where the drug must not be used), such as active liver disease or pregnancy. They also list rare but clinically serious side effects, such as Rhabdomyolysis (a severe muscle condition) and Hepatic failure, which are described as conditions where patient monitoring is necessary.


Q: Do I need to change my diet while taking Alten?

Official patient information states that therapy with Alten is typically used alongside a healthy diet plan agreed upon with a doctor. This plan may involve measures to control body weight and reduce the intake of saturated fats and cholesterol-rich foods.


Q: Does Alten affect your ability to drive?

Official advice states that Alten generally does not affect the ability to drive or operate machinery. However, because it can cause a feeling of dizziness in some patients, official advice notes that caution regarding driving is customary until the effects are known.


Q: Can elderly patients use Alten?

Alten is indicated for use in adult patients, and studies have examined its effects in older patients (65 and over). Official documents also note that advanced age is a factor associated with an increased risk of muscle disorders like myopathy, which is why monitoring may be necessary.


Q: How long does the effect of one dose of Alten usually last?

The mean elimination half-life (the time it takes for half the drug to leave the bloodstream) of the active ingredient is approximately 14 hours. However, the overall half-life of its cholesterol-lowering activity is longer—approximately 20 to 30 hours—due to its active metabolites.


Q: Can people with high blood pressure take Alten?

Clinical studies have demonstrated the safety and efficacy of using Alten in patients who also have high blood pressure (hypertension) and high cholesterol. It is often used effectively in combination with blood pressure-lowering medication.


Q: Is it true that research for Alten is still ongoing?

Yes. Research is described in official literature as still ongoing or emerging. This includes long-term follow-up studies and investigations into the effects in specific patient populations, such as older adults without established heart disease.


Q: How long after stopping Alten will it be completely out of my system?

The clearance of a drug from the body is related to its half-life, which for Alten's cholesterol-lowering activity is approximately 20 to 30 hours. Based on this, most of the active substance will be cleared within several days after the last dose.


Q: Is Alten known to cause weight gain or loss?

Official adverse reaction data reports that weight gain is listed as an uncommon side effect of Alten. Weight loss is not specifically mentioned in the regulatory adverse event listing for the product.


Q: Are there any restrictions on strenuous exercise while taking Alten?

Official safety information includes consulting with a healthcare provider regarding suitable exercise. Excessive physical exercise is noted as a risk factor that may increase the potential for muscle pain or weakness (myopathy) while taking statins.


Q: What color is the Alten tablet/capsule?

Alten contains the active ingredient Atorvastatin, which is commonly formulated as a film-coated tablet. These tablets are typically white and either oval or round in shape, though the exact appearance can vary depending on the dosage strength.


Q: Is Alten available as a generic medicine?

Alten is the established brand name for the active ingredient Atorvastatin. The ingredient is widely available globally as a generic medicine, typically marketed under its chemical name.

How should Alten be stored and disposed of?

Official Storage and Disposal Requirements for Alten

Alten (Atorvastatin) tablets must be stored at room temperature, specifically not above 25 C (77 F), according to official labeling. The medicine requires protection away from excess heat, moisture, and direct light and must be kept from freezing.

Classification Requirement
Temperature Range Store at room temperature (below 25 C)
Protection Protect from heat, moisture, and direct light
Packaging Keep in the closed container it came in
Child Safety Keep out of the sight and reach of children

For disposal, the regulatory mandate is to not throw away the medicine via wastewater or household waste. All unused or expired product must be disposed of in accordance with local requirements; patients are advised to consult a pharmacist for guidance on proper collection and handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alten found in:

A-Z Index: